Phoenix, ARIZONA5 Active Studies

Atrial Fibrillation Clinical Trials in Phoenix, ARIZONA

Find 5 actively recruiting atrial fibrillation clinical trials in Phoenix, ARIZONA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
7,630
Enrolling

Recruiting Atrial Fibrillation Studies in Phoenix

RecruitingPhoenix, ARIZONANCT05836987

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation ...

5,350 participants
Johns Hopkins University
View Study Details
RecruitingPhoenix, ARIZONANCT05712200

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their respon...

1,900 participants
Anthos Therapeutics, Inc.
View Study Details
RecruitingPhoenix, ARIZONANCT06499857

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, a...

200 participants
University of Chicago
View Study Details
RecruitingPhoenix, ARIZONANCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in par...

120 participants
Incyte Corporation
View Study Details
RecruitingPhoenix, ARIZONANCT05643638

A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD

This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with H...

60 participants
Cynata Therapeutics Limited
View Study Details

About Atrial Fibrillation Clinical Trials in Phoenix

Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.

There are currently 5 atrial fibrillation clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 7,630 participants. Research is being sponsored by Johns Hopkins University, Anthos Therapeutics, Inc., University of Chicago and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atrial Fibrillation Clinical Trials in Phoenix — FAQ

Are there atrial fibrillation clinical trials in Phoenix?

Yes, there are 5 atrial fibrillation clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What atrial fibrillation treatments are being tested?

The 5 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.

Data updated March 2, 2026 from ClinicalTrials.gov